Catalent announces plans to increase biologic development and manufacturing capabilities at new Wisconsin biologics facility

Catalent's current facility is located in Middleton, Wisconsin.

The new facility will quadruple the capacity of Catalent's current facility, allowing the company to enhance its offerings in the development and manufacturing of biologic products. Additionally, the expansion will enhance the efficiency and output of Catalent's GPExâ cell line engineering technology and process development capabilities, as well as other mammalian cell lines. This combination of technology and capabilities is designed to provide Catalent's customers with a competitive advantage by producing stable, high-yielding mammalian cell lines and robust manufacturing processes with industry leading timelines.

“Plans for the biologics facility are designed to meet our customers' needs through improved delivery of integrated services in the areas of biologic development and manufacturing,” stated Kent Payne, Ph.D., Vice President and General Manager of Catalent's Biologics business. “This is the first step in a series of strategic development initiatives designed to enhance our offerings in this rapidly expanding market.”

Supported by numerous process upgrades and increased capabilities in process development, the new facility will include three individual current Good Manufacturing Practice (cGMP) compliant production suites that will increase Phase I and II production capacity up to 1,000L bioreactors.

Catalent will also transition from stainless steel bioreactors to single use bioreactors. This transition will further increase capacity by increasing the number of batches produced per suite and allow greater flexibility in the scale of cGMP manufacturing capacity offered to Catalent's customers.